<DOC>
	<DOCNO>NCT02277691</DOCNO>
	<brief_summary>Primary objective study evaluate safety long-term administration TAK-536 , amlodipine ( AML ) , hydrochlorothiazide ( HCTZ ) patient essential hypertension .</brief_summary>
	<brief_title>A Phase III Long-term Study TAK-536TCH Patients With Essential Hypertension</brief_title>
	<detailed_description>This Phase III , open-label , multicenter study evaluate safety efficacy long-term administration TAK-536 20 mg , amlodipine ( AML ) 5 mg , hydrochlorothiazide ( HCTZ ) 12.5 mg daily 52 week patient essential hypertension poorly control TAK-536CCB .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<criteria>1 . In opinion investigator subinvestigator , participant capable understand comply protocol requirement . 2 . The participant sign date inform consent form prior initiation study procedure . 3 . The participant essential hypertension . 4 . The participant 's clinic sit systolic blood pressure ( SBP ) &lt; 180 mmHg clinic sit diastolic blood pressure ( DBP ) &lt; 110 mmHg start runin period ( Week 4 ) . Patients receive treatment threedrug antihypertensive within 4 week prior start runin period must clinic sit SBP &lt; 160 mmHg clinic sit DBP &lt; 100 mmHg . 5 . The participant 's clinic sit blood pressure Week 2 end runin period ( Week 0 ) : &lt; Patients without concurrent diabetes mellitus chronic kidney disease ( CKD ) &gt; Sitting SBP ≥ 140 mmHg sit DBP ≥ 90 mmHg &lt; Patients concurrent diabetes mellitus CKD &gt; Sitting SBP ≥ 130 mmHg sit DBP ≥ 80 mmHg 6 . The participant 's clinic sit SBP &lt; 160 mmHg clinic sit DBP &lt; 100 mmHg end runin period ( Week 0 ) . 7 . Sex : male and/or female ; Aged 20 year old time inform consent obtain . 8 . Hospitalization status : Outpatient 9 . A female participant childbearing potential sexually active nonsterilized male partner agree use routinely adequate contraception signing inform consent 1 month end study . 1 . The participant receive investigational compound within 12 week prior start runin period . 2 . The participant participate clinical trial postmarketing study within 30 day prior start runin period . 3 . The participant immediate family member , study site employee , dependant relationship study site employee involve conduct study ( e.g . spouse , parent , child , sibling ) , may consent duress . 4 . The participant require treatment prohibited concomitant drug study . 5 . The participant history hypersensitivity allergy TAK536 , AML , HCTZ , thiazide diuretic analog , dihydropyridine drug , analog TAK536TCH . 6 . The participant may , opinion investigator subinvestigator , experience excessive increase blood pressure change discontinue premedication . 7 . The participant previously receive treatment threeingredient antihypertensive drug three ingredient find TAK536TCH . 8 . The participant receive therapy 4 different antihypertensive agent within 4 week prior start runin period . 9 . The participant secondary malignant hypertension . 10 . The participant 's clinic sit SBP Week 4 differs leave right arm ≥ 20 mmHg . 11 . The participant apparent white coat hypertension show white coat effect . 12 . The participant lead nocturnal lifestyle due work night shift another reason . 13 . The participant sleep apnea syndrome requiring treatment . 14 . The participant follow cardiovascular disease : Cardiac disease : Myocardial infarction , coronary arterial revascularization , severe valvular disorder , atrial fibrillation , follow disorder drug treatment require : angina pectoris , congestive heart failure , arrhythmia Cerebrovascular disorder : Cerebral infarction/cerebral hemorrhage , transient ischemic attack Vascular disease : Peripheral artery disease intermittent claudication , artery dissection , aneurysm Advanced hypertensive retinopathy : With bleed exudate/papilledema 15 . The participant clinically apparent hepatic disorder ( e.g. , alanine aminotransferase ( AST ) aspartate aminotransferase ( ALT ) Week 2 runin period ≥ 2.5 time upper limit normal ) . 16 . The participant clinically apparent hepatic disorder ( e.g. , alanine aminotransferase ( AST ) aspartate aminotransferase ( ALT ) Week 2 runin period ≥ 2.5 time upper limit normal ) . 17 . The participant clinically severe renal disorder ( e.g. , eGFRcreat laboratory test perform Week 2 runin period &lt; 30 mL/minute/1.73 m2 ) . 18 . The participant 's body fluid sodium potassium level markedly low high . 19 . The participant gout gout within 24 week prior start runin period hyperuricemia require drug treatment . 20 . The participant poorly control diabetes ( e.g. , HbA1c ≥ 7.4 % laboratory test perform Week 2 runin period ) . 21 . The participant malignancy . 22 . If female , participant pregnant lactate intend become pregnant , , within 1 month participate study ; intend donate ova time period.. 23 . The participant history drug abuse ( define illicit drug use ) history alcohol abuse within 2 year prior start runin period . 24 . The participant otherwise find ineligible investigator subinvestigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Pharmacological therapy</keyword>
</DOC>